Mainz Biomed Reviews 2025 Achievements and Future Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Mainz Biomed reviewed its major accomplishments for the year ended December 31, 2025. "I'm extremely pleased with the achievements of our team during 2025 as we advance our ambitious growth strategy, driven by our eAArly DETECT 2 study and continued progress in our pancreatic cancer screening program," commented Guido Baechler, CEO of Mainz Biomed. "Looking ahead to the first half of 2026, we expect to complete our eAArly DETECT 2 feasibility study, which will be the launching point for our ReconAAsense US FDA pivotal colorectal cancer study in 2026, and to announce our next steps in advancing our blood-based screening test for the early detection of pancreatic cancer."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MYNZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MYNZ
Wall Street analysts forecast MYNZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYNZ is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.240
Low
14.00
Averages
14.00
High
14.00
Current: 1.240
Low
14.00
Averages
14.00
High
14.00
About MYNZ
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mainz Biomed Launches eAArly DETECT 2 Clinical Study Covering 2,000 Patients
- Clinical Study Launch: Mainz Biomed initiates the eAArly DETECT 2 clinical study, aiming to evaluate its next-generation colorectal cancer test on approximately 2,000 average-risk patients, which will validate previous leading results and lay the groundwork for future FDA pivotal trials.
- Market Expansion: The ColoAlert® test has received registration from the UK’s MHRA and Swissmedic, marking its debut in the Swiss market and significantly enhancing Mainz Biomed's market share and influence across Europe.
- Strategic Partnerships: The strategic partnership with labor team w ag introduces ColoAlert® to the Swiss market, while collaboration with OncoVanguard8 aims to expand its reach into South America, demonstrating the company's commitment to global market expansion.
- Funding Support: Mainz Biomed's pancreatic cancer project receives public funding from Germany's ISB, covering up to 50% of total project costs, which not only enhances the project's feasibility but also reflects government endorsement of its scientific value.
Continue Reading
Mainz Biomed Integrates ColoAlert® Test into DoctorBox Platform in Germany
- Market Expansion: Mainz Biomed's ColoAlert® test has been integrated into DoctorBox, a leading digital health platform in Germany, marking a significant milestone in the company's European growth strategy and expected to greatly enhance access to early cancer detection.
- User Base: With over one million registered users and more than ten million test results, the integration of ColoAlert® will further solidify DoctorBox's leadership in digital preventive healthcare, driving business growth for Mainz Biomed.
- Innovative Collaboration: The partnership with DoctorBox not only lowers barriers to colorectal cancer screening but also enhances user engagement through at-home testing, aligning with modern healthcare service trends.
- Importance of Preventive Care: With approximately 60,000 new colorectal cancer cases diagnosed annually in Germany, the introduction of ColoAlert® provides an effective early detection solution to meet this demand, further advancing the development of personalized preventive healthcare.
Continue Reading